Leerink Swann Increases Bristol-Myers Squibb Co (BMY) Price Target to $72.00

Bristol-Myers Squibb Co (NYSE:BMY) had its target price lifted by Leerink Swann from $61.00 to $72.00 in a report released on Monday. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Leerink Swann’s price target would suggest a potential upside of 11.77% from the stock’s current price.

A number of other analysts also recently weighed in on the stock. Vetr downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $63.81 price target for the company. in a research report on Wednesday, August 9th. BidaskClub raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Jefferies Group LLC reissued a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, July 12th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Finally, UBS AG reissued a “buy” rating and set a $72.00 price target (up previously from $62.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $64.53.

Bristol-Myers Squibb (NYSE:BMY) traded down 0.11% on Monday, reaching $64.35. 2,395,449 shares of the company’s stock traded hands. The firm has a market capitalization of $105.53 billion, a P/E ratio of 23.50 and a beta of 1.19. Bristol-Myers Squibb has a 52 week low of $46.01 and a 52 week high of $66.10. The stock has a 50-day moving average of $63.37 and a 200 day moving average of $57.29.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a net margin of 17.92% and a return on equity of 25.24%. The business’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.69 earnings per share. On average, equities analysts expect that Bristol-Myers Squibb will post $2.98 EPS for the current fiscal year.

WARNING: “Leerink Swann Increases Bristol-Myers Squibb Co (BMY) Price Target to $72.00” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://ledgergazette.com/2017/10/23/leerink-swann-increases-bristol-myers-squibb-co-bmy-price-target-to-72-00.html.

In related news, Director Theodore R. Samuels II bought 6,000 shares of the business’s stock in a transaction on Wednesday, August 2nd. The shares were bought at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the purchase, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the sale, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Tradewinds Capital Management LLC lifted its stake in Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 500 shares during the last quarter. Atlantic Trust LLC bought a new stake in Bristol-Myers Squibb in the second quarter valued at $111,000. Welch Investments LLC lifted its stake in Bristol-Myers Squibb by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 79 shares during the last quarter. Blue Chip Partners Inc. lifted its stake in Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an a

A number of other analysts also recently weighed in on the stock. Vetr downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $63.81 price target for the company. in a research report on Wednesday, August 9th. BidaskClub raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Jefferies Group LLC reissued a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, July 12th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Finally, UBS AG reissued a “buy” rating and set a $72.00 price target (up previously from $62.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $64.53.

Bristol-Myers Squibb (NYSE:BMY) traded down 0.11% on Monday, reaching $64.35. 2,395,449 shares of the company’s stock traded hands. The firm has a market capitalization of $105.53 billion, a P/E ratio of 23.50 and a beta of 1.19. Bristol-Myers Squibb has a 52 week low of $46.01 and a 52 week high of $66.10. The stock has a 50-day moving average of $63.37 and a 200 day moving average of $57.29.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a net margin of 17.92% and a return on equity of 25.24%. The business’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.69 earnings per share. On average, equities analysts expect that Bristol-Myers Squibb will post $2.98 EPS for the current fiscal year.

WARNING: “Leerink Swann Increases Bristol-Myers Squibb Co (BMY) Price Target to $72.00” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://ledgergazette.com/2017/10/23/leerink-swann-increases-bristol-myers-squibb-co-bmy-price-target-to-72-00.html.

In related news, Director Theodore R. Samuels II bought 6,000 shares of the business’s stock in a transaction on Wednesday, August 2nd. The shares were bought at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the purchase, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the sale, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Tradewinds Capital Management LLC lifted its stake in Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 500 shares during the last quarter. Atlantic Trust LLC bought a new stake in Bristol-Myers Squibb in the second quarter valued at $111,000. Welch Investments LLC lifted its stake in Bristol-Myers Squibb by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 79 shares during the last quarter. Blue Chip Partners Inc. lifted its stake in Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 17 shares during the last quarter. Finally, American National Bank lifted its stake in Bristol-Myers Squibb by 11.7% in the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 225 shares during the last quarter. Institutional investors own 68.84% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply